Other Meetings

Other Meetings

On-site reporting from other meetings and summits in the hematology/oncology arena

On location

Oncology Nurse–Led Patient Education Program Improves Adherence to Oral Cancer Therapies

CHICAGO--There are benefits to allowing patients with cancer to take oral cancer therapies at home instead of receiving infusions at the clinic, however it...
On location

Examining Venetoclax Combinations in Older Patients with Acute Myeloid Leukemia

Older patients with acute myeloid leukemia (AML) who are unable to receive standard 7+3 induction chemotherapy have limited treatment options. Selective targeting of the...
On location

Pacritinib for Myelofibrosis: Follow-Up from PERSIST-1

Results from the phase III PERSIST-1 study presented at the 2015 ASCO Meeting showed that the JAK2 inhibitor pacritinib led to more effective spleen...
On location

Risk for Venous Thromboembolism Changes Throughout Multiple Myeloma Disease Course

Nearly one in three patients will experience venous thromboembolism (VTE) within the first year of a multiple myeloma (MM) diagnosis, but new research presented...
On location

Acalabrutinib Safe in Patients with Previously Untreated Chronic Lymphocytic Leukemia

Preliminary results from a phase I/II study of the second-generation Bruton’s tyrosine kinase (BTK) inhibitor acalabrutinib in patients with previously untreated chronic lymphocytic leukemia...
On location

Study Highlights How the FDA is Improving Expanded Access

When physicians believe that a patient with cancer may benefit from an agent that has not yet been approved by the U.S. Food and...
On location

Early-Phase Trial Suggests CAR T-Cell Therapy Safe for Patients with Non-Hodgkin Lymphoma

Results from the phase I ZUMA-1 trial presented at the AACR Annual Meeting suggest that KTE-C19, a chimeric antigen receptor (CAR), is a safe...

Novel Combination Therapy Targets Cancer Stem Cells in Multiple Myeloma

Cancer stem cells (CSCs) have been identified in many diseases, including multiple myeloma (MM), but it is unclear how their frequencies change during treatment...
On location

Spliceosome Inhibition Is a Potential Therapeutic Option for Patients with ALL and AML

The novel therapeutic strategy of spliceosome targeting is a promising option for patients with acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML), including...
On location

Study Examines Novel Second-Generation Selective Inhibitor of Nuclear Export for ALL

KPT-8602, a second-generation selective inhibitor of nuclear export (SINE), demonstrated similar anti-leukemic activity and better tolerability than the first-generation SINE selinexor, according to early...
Advertisement

Current Issue

November 2020 Bonus ASH Annual Meeting Preview Edition (Volume 6, Issue...

View issue flipbook November 2020 Bonus ASH Annual Meeting Preview Edition Volume 6, Issue 14This issue offers a behind-the-scenes look at this year's virtual annual meeting,...

Block title